Miaomiao Wang, Zhike Zhou, Yingying Wang, Lixin Wang
{"title":"The gene-panel obtained by anti-PD-1 monotherapy for melanoma reveals prognostic markers and therapeutic targets.","authors":"Miaomiao Wang, Zhike Zhou, Yingying Wang, Lixin Wang","doi":"10.1080/1120009X.2025.2465013","DOIUrl":null,"url":null,"abstract":"<p><p>To search for key drug resistance biomarkers and potential chemotherapeutic agents for combination therapy in melanoma patients. The common up-regulated differentially expressed genes were acquired from two cohort studies, GSE91061 and PRJEB23709. Univariate and multivariate Cox regression survival analyses were performed to screen for important prognostic biomarkers. A multi-gene panel including <i>APP</i>, <i>ARHGAP42</i>, <i>GSTA4</i> and <i>UCHL1</i>, not only plays an important role in prognostic indicators, but also in predicting the probability of resistance to anti-PD-1 in patients with melanoma. Chemotherapy drug response models found five potential drugs, including all-trans retinoic acid, doxorubicin, etoposide, methotrexate and MG-132, were significantly associated with target genes in gene-panel. Molecular docking confirmed that potential drugs have good binding ability to target genes <i>APP</i>, <i>GSTA4</i> and <i>UCHL1,</i> suggesting that the multi-gene panel is expected to provide assistance for drug resistance prediction and prognosis assessment and combination therapy in patients with anti-PD-1 resistant melanoma.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2465013","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
To search for key drug resistance biomarkers and potential chemotherapeutic agents for combination therapy in melanoma patients. The common up-regulated differentially expressed genes were acquired from two cohort studies, GSE91061 and PRJEB23709. Univariate and multivariate Cox regression survival analyses were performed to screen for important prognostic biomarkers. A multi-gene panel including APP, ARHGAP42, GSTA4 and UCHL1, not only plays an important role in prognostic indicators, but also in predicting the probability of resistance to anti-PD-1 in patients with melanoma. Chemotherapy drug response models found five potential drugs, including all-trans retinoic acid, doxorubicin, etoposide, methotrexate and MG-132, were significantly associated with target genes in gene-panel. Molecular docking confirmed that potential drugs have good binding ability to target genes APP, GSTA4 and UCHL1, suggesting that the multi-gene panel is expected to provide assistance for drug resistance prediction and prognosis assessment and combination therapy in patients with anti-PD-1 resistant melanoma.
期刊介绍：
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
